Arbutus Biopharma Corporation (ABUS) has had a fantastic run since Oct, going from under a dollar, all the way up to 3 3/4, it consolidated in a 3-wave, corrective pullback flag, and on Wednesday, it popped with a breakaway gap, up 43 cents, or 15.3%, to 3.24, six points off the 3.30 session high, on 1.6 million shares traded. That’s the biggest volume in about two months. Now, let’s see if it will retest 3 3/4, and then 4 1/4. I think the swing targets are 5 1/2 and 6 3/4

Adaptimmune Therapeutics plc (ADAP) is a swing trade of ours that we are watching very carefully. It broke out of a coil on Wednesday and ran 46 cents, or 11.39%, to 4.50, after reaching a high of 4.65, on 1.7 million shares traded. The volume increased a little bit but not enough. If it gets through 4.80-.85, then we’re looking at 6 1/4.

Fulgent Genetics, Inc. (FLGT) also broke out of a coil on Wednesday, and jumped 1.52, or 11%, to 15.42, not far off the session high at 15.50, on 458,587 shares traded. That’s the biggest volume in about two months. It’s awfully solid here, and if it can get through this zone, and then take out 16 1/2, that’s my target. Mid-channel target is around 18 1/2-19.

Puma Biotechnology, Inc. (PBYI) exploded Wednesday, jumping 3.98 or 38%, to 14.56, after reaching a high of 15.00, on a whopping 23 million shares traded. I’m looking for a test now of about the 17 3/4-18 range, and then we’ll look at 20 going forward.

Revance Therapeutics, Inc. (RVNC) broke out of a wedge as well on Wednesday at the top of the channel, gaining another 1.53, or 6.5%, to 25.07, just two cents off the session and 52-week high at 25.09, on 615,691 shares traded. If it accelerates here, I would be looking at 27 next. With resistance overhead, it may see 30.

Selecta Biosciences, Inc. (SELB) popped 76 cents, or 20.8%, to 4.41, after reaching the session and 52-week high of 4.79, on 1.5 million shares traded on Wednesday. On the daily chart, it looks like it may extend to the 6 1/4 range.

Stocks on the long side included Arbutus Biopharma Corporation (ABUS), Adaptimmune Therapeutics plc (ADAP), Anavex Life Sciences Corp. (AVXL), BioXcel Therapeutics, Inc. (BTAI), Clovis Oncology, Inc. (CLVS), Cyclerion Therapeutics, Inc. (CYCN), 3D Systems Corporation (DDD), Fulgent Genetics, Inc. (FLGT), Grayscale Bitcoin Trust (BTC) (GBTC), MasterCraft Boat Holdings, Inc. (MCFT), Mallinckrodt plc (MNK), Nautilus, Inc. (NLS), O-I Glass, Inc. (OI), Puma Biotechnology, Inc. (PBYI), Revance Therapeutics, Inc. (RVNC), SmileDirectClub, Inc. (SDC), and Selecta Biosciences, Inc. (SELB).